Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 7/20 | 0.43 |
| ▸ | BIRC3 | Q13489 | 6/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 6/20 | 0.43 |
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | MC1R | Q01726 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13164551 | 0.87 | ELANE (0.52) | XIAPBIRC3BIRC2ELANEABCB1 | |
| SCHEMBL13164553 | 0.85 | XIAP (0.55) | XIAPBIRC3BIRC2 | |
| SCHEMBL13746928 | 0.85 | XIAP (0.55) | XIAPBIRC3BIRC2 | |
| SCHEMBL13164533 | 0.85 | XIAP (0.49) | XIAPBIRC3BIRC2 | |
| SCHEMBL20152040 | 0.83 | AGTR2 (0.40) | XIAPBIRC3BIRC2ELANEAGTR2 | |
| SCHEMBL20137190 | 0.83 | AGTR2 (0.40) | XIAPBIRC3BIRC2ELANEAGTR2 | |
| SCHEMBL20137192 | 0.83 | AGTR2 (0.40) | XIAPBIRC3BIRC2ELANEAGTR2 | |
| SCHEMBL20137204 | 0.83 | AGTR2 (0.40) | XIAPBIRC3BIRC2ELANEAGTR2 | |
| SCHEMBL20137203 | 0.83 | AGTR2 (0.40) | XIAPBIRC3BIRC2ELANEAGTR2 | |
| SCHEMBL20137242 | 0.82 | ELANE (0.39) | XIAPBIRC3BIRC2ELANEAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365614-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-06-14 | — | — | US | disclosed |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | PHARMASCIENCE INC. (CA) | 2014-11-13 | — | — | US | disclosed |
| US-8765681-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20130071411-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-20100221261-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-09-02 | — | — | US | disclosed |
| US-20100221261-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-09-02 | — | — | US | disclosed |
| US-7645741-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | AEGERA THERAPEUTICS, INC. | 2010-01-12 | — | — | US | disclosed |
| US-7645741-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | AEGERA THERAPEUTICS, INC. | 2010-01-12 | — | — | US | disclosed |
| US-7579320-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-08-25 | — | — | US | disclosed |
| US-7579320-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-08-25 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| WO-2007104162-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221261-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | XIAP 6/4885BIRC3 3/4885BIRC2 2/4885 |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | BIRC2, BIRC7, BIRC5 | XIAP 6/4885BIRC3 4/4885BIRC2 1/4885 |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | XIAP 2/4885BIRC3 7/4885BIRC2 3/4885 |
| US-20130071411-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | XIAP 6/4885BIRC3 3/4885BIRC2 2/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | XIAP 2/4885BIRC3 8/4885BIRC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.